MP 0423
Alternative Names: MP-0423Latest Information Update: 28 Nov 2024
Price :
$50 *
At a glance
- Originator Molecular Partners AG
- Class Antivirals; Proteins
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Nov 2024 No recent reports of development identified for preclinical development in COVID-2019-infections in Switzerland
- 28 Nov 2024 No recent reports of development identified for preclinical development in COVID-2019-infections(Prevention) in Switzerland
- 04 Feb 2021 Pharmacodynamics data from a pre-clinical trial in COVID-2019 infections released by Molecular Partners